雅培Abbott Laboratories （ABT）2024年第四季度及全年业绩报告（英文版）（15页）.pdf

1、ABBOTT REPORTS FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS;ISSUES2025 FINANCIAL OUTLOOKFourth-quarter sales of$11.0 billion;full-year 2024 sales of$42.0 billionFourth-quarter reported sales increased 7.2 percent;organic sales growth for the underlying base businessincreased 10.1 percent1Full-year 2024

2、 reported sales increased 4.6 percent;organic sales growth for the underlying base businessincreased 9.6 percent2Abbott projects full-year 2025 organic sales growth to be in the range of 7.5%to 8.5%ABBOTT PARK,Ill.,Jan.22,2025/PRNewswire/-Abbott(NYSE:ABT)today announced financial results for the fou

3、rth quarter endedDec.31,2024.Fourth-quarter sales increased 7.2 percent on a reported basis,8.8 percent on an organic basis,and 10.1 percent on anorganic basis,excluding COVID-19 testing-related sales.Fourth-quarter GAAP diluted EPS of$5.27 and adjusted diluted EPS of$1.34,which excludes specified i

4、tems(see table titledNon-GAAP Reconciliation of Financial Information).Full-year 2024 sales of$42.0 billion increased 4.6 percent on a reported basis,7.1 percent on an organic basis,and 9.6percent on an organic basis,excluding COVID-19 testing-related sales.Full-year 2024 gross margin as a percent o

5、f sales improved 60 basis points on a GAAP basis compared to 2023 and improved70 basis points on an adjusted basis.Full-year 2024 GAAP diluted EPS of$7.64 and adjusted diluted EPS of$4.67,which excludes specified items(see table titledNon-GAAP Reconciliation of Financial Information).For the full-ye

6、ar 2024,Abbott achieved the upper end of the initial guidance ranges the company provided in January 2024 forboth organic sales growth and adjusted earnings per share.During 2024,Abbott announced more than 15 new growth opportunities coming from the companys highly productive R&Dpipeline.These inclu